Literature DB >> 7876602

Viral shedding and fecal IgA response after Norwalk virus infection.

P C Okhuysen1, X Jiang, L Ye, P C Johnson, M K Estes.   

Abstract

Protection is not conferred by preexposure to Norwalk virus (NV). By use of an ELISA with baculovirus-expressed recombinant NV (rNV) capsid protein, the pattern of NV fecal shedding and the protective effect of rNV-specific fecal IgA (flgA) were investigated in volunteers who were repeatedly challenged with NV. After the first challenge, ill volunteers were significantly more likely than well volunteers to have NV antigen in their stool (P < .05). After challenge, antigen shedding was detected on days 1-13; ill volunteers shed the antigen longer (P = .02). A higher prechallenge rNV-specific flgA geometric mean titer was found in ill compared with well volunteers (P < .05) and in infected versus noninfected volunteers (P < .05). NV shedding was common after infection and was present up to 2 weeks after challenge. Preexisting rNV-specific flgA, like serum IgG, is not protective and may be a marker for symptomatic disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876602     DOI: 10.1093/infdis/171.3.566

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Concentration of norovirus during wastewater treatment and its impact on oyster contamination.

Authors:  John Flannery; Sinéad Keaveney; Paulina Rajko-Nenow; Vincent O'Flaherty; William Doré
Journal:  Appl Environ Microbiol       Date:  2012-02-24       Impact factor: 4.792

2.  Mucosal and Cellular Immune Responses to Norwalk Virus.

Authors:  Sasirekha Ramani; Frederick H Neill; Antone R Opekun; Mark A Gilger; David Y Graham; Mary K Estes; Robert L Atmar
Journal:  J Infect Dis       Date:  2015-01-29       Impact factor: 5.226

Review 3.  The role of prolonged viral gastrointestinal infections in the development of immunodeficiency-related enteropathy.

Authors:  Annick A J M van de Ven; David P Hoytema van Konijnenburg; Annemarie M J Wensing; Joris M van Montfrans
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

4.  Serological correlate of protection against norovirus-induced gastroenteritis.

Authors:  Amanda Reeck; Owen Kavanagh; Mary K Estes; Antone R Opekun; Mark A Gilger; David Y Graham; Robert L Atmar
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

Review 5.  Diagnosis of noncultivatable gastroenteritis viruses, the human caliciviruses.

Authors:  R L Atmar; M K Estes
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

6.  Outbreak of norovirus illness associated with a swimming pool.

Authors:  L J Podewils; L Zanardi Blevins; M Hagenbuch; D Itani; A Burns; C Otto; L Blanton; S Adams; S S Monroe; M J Beach; M Widdowson
Journal:  Epidemiol Infect       Date:  2006-11-01       Impact factor: 2.451

7.  Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.

Authors:  Yuanmei Ma; Yue Duan; Yongwei Wei; Xueya Liang; Stefan Niewiesk; Michael Oglesbee; Jianrong Li
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

8.  Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses.

Authors:  Vesselin T Tomov; Lisa C Osborne; Douglas V Dolfi; Gregory F Sonnenberg; Laurel A Monticelli; Kathleen Mansfield; Herbert W Virgin; David Artis; E John Wherry
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

9.  Evaluation and validation of real-time reverse transcription-pcr assay using the LightCycler system for detection and quantitation of norovirus.

Authors:  Xiaoli Pang; Bonita Lee; Linda Chui; Jutta K Preiksaitis; Stephan S Monroe
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

10.  Antibody is critical for the clearance of murine norovirus infection.

Authors:  Karen A Chachu; David W Strong; Anna D LoBue; Christiane E Wobus; Ralph S Baric; Herbert W Virgin
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.